Utility of Targeted, Amplicon-Based Deep Sequencing To Detect Resistance to First-Line Tuberculosis Drugs in Botswana.

Authors :: Wang Q
Modongo C
Allender C
Engelthaler DM
Warren RM
Zetola NM
Shin SS
Source :: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2019 Oct 22; Vol. 63 (11). Date of Electronic Publication: 2019 Oct 22 (Print Publication: 2019).
Publication Year :: 2019
Abstract: Multidrug-resistant tuberculosis (TB) is an alarming threat, and targeted deep sequencing (DS) may be an effective method for rapid identification of drug-resistant profiles, including detection of heteroresistance. We evaluated the sensitivity and specificity of targeted DS versus phenotypic drug susceptibility testing (pDST) among patients starting first-line anti-TB therapy in Botswana. Overall, we found high concordance between DS and pDST. Lower sensitivity of DS, which targets established high-confidence resistance variants, was observed for detecting isoniazid resistance among HIV-infected patients.<br /> (Copyright © 2019 American Society for Microbiology.)

Subjects :: Adult
Botswana
Female
High-Throughput Nucleotide Sequencing methods
Humans
Isoniazid therapeutic use
Male
Microbial Sensitivity Tests methods
Middle Aged
Phenotype
Sensitivity and Specificity
Young Adult
Antitubercular Agents therapeutic use
Mycobacterium tuberculosis drug effects
Mycobacterium tuberculosis genetics
Tuberculosis, Multidrug-Resistant drug therapy

Full Text Access

Tools